Tamsyn E Van Rheenen1,2,3, Vanessa Cropley1,2, Andrew Zalesky1,4, Chad Bousman1, Ruth Wells5,6, Jason Bruggemann5,6, Suresh Sundram7,8,9, Danielle Weinberg5,6, Roshel K Lenroot5,6,10, Avril Pereira1,7, Cynthia Shannon Weickert1,5,6,10, Thomas W Weickert1,5,6,10, Christos Pantelis1,4,7. 1. Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Melbourne, Australia. 2. Centre for Mental Health, Faculty of Health, Arts and Design, School of Health Sciences, Swinburne University, Melbourne, Australia. 3. Cognitive Neuropsychiatry Laboratory, Monash Alfred Psychiatry Research Centre (MAPrc), The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia. 4. Department of Electrical and Electronic Engineering, University of Melbourne, Parkville, Australia. 5. School of Psychiatry, University of New South Wales, Sydney, Australia. 6. Neuroscience Research Australia, Sydney, Australia. 7. Florey Institute of Neuroscience and Mental Health, Parkville, Australia. 8. Mental Health Program, Monash Health, Clayton, Australia. 9. Department of Psychiatry, School of Clinical Sciences, Monash University, Clayton, Australia. 10. Schizophrenia Research Institute, Sydney, Australia.
Abstract
Objective: Progress toward understanding brain mechanisms in psychosis is hampered by failures to account for within-group heterogeneity that exists across neuropsychological domains. We recently identified distinct cognitive subgroups that might assist in identifying more biologically meaningful subtypes of psychosis. In the present study, we examined whether underlying structural brain abnormalities differentiate these cognitively derived subgroups. Method: 1.5T T1 weighted structural scans were acquired for 168 healthy controls and 220 patients with schizophrenia/schizoaffective disorder. Based on previous work, 47 patients were categorized as being cognitively compromised (impaired premorbid and current IQ), 100 as cognitively deteriorated (normal premorbid IQ, impaired current IQ), and 73 as putatively cognitively preserved (premorbid and current IQ within 1 SD of controls). Global, subcortical and cortical volume, thickness, and surface area measures were compared among groups. Results: Whole cortex, subcortical, and regional volume and thickness reductions were evident in all subgroups compared to controls, with the largest effect sizes in the compromised group. This subgroup also showed abnormalities in regions not seen in the other patient groups, including smaller left superior and middle frontal areas, left anterior and inferior temporal areas and right lateral medial and inferior frontal, occipital lobe and superior temporal areas. Conclusions: This pattern of more prominent brain structural abnormalities in the group with the most marked cognitive impairments-both currently and putatively prior to illness onset, is consistent with the concept of schizophrenia as a progressive neurodevelopmental disorder. In this group, neurodevelopmental and neurodegenerative factors may be important for cognitive function.
Objective: Progress toward understanding brain mechanisms in psychosis is hampered by failures to account for within-group heterogeneity that exists across neuropsychological domains. We recently identified distinct cognitive subgroups that might assist in identifying more biologically meaningful subtypes of psychosis. In the present study, we examined whether underlying structural brain abnormalities differentiate these cognitively derived subgroups. Method: 1.5T T1 weighted structural scans were acquired for 168 healthy controls and 220 patients with schizophrenia/schizoaffective disorder. Based on previous work, 47 patients were categorized as being cognitively compromised (impaired premorbid and current IQ), 100 as cognitively deteriorated (normal premorbid IQ, impaired current IQ), and 73 as putatively cognitively preserved (premorbid and current IQ within 1 SD of controls). Global, subcortical and cortical volume, thickness, and surface area measures were compared among groups. Results: Whole cortex, subcortical, and regional volume and thickness reductions were evident in all subgroups compared to controls, with the largest effect sizes in the compromised group. This subgroup also showed abnormalities in regions not seen in the other patient groups, including smaller left superior and middle frontal areas, left anterior and inferior temporal areas and right lateral medial and inferior frontal, occipital lobe and superior temporal areas. Conclusions: This pattern of more prominent brain structural abnormalities in the group with the most marked cognitive impairments-both currently and putatively prior to illness onset, is consistent with the concept of schizophrenia as a progressive neurodevelopmental disorder. In this group, neurodevelopmental and neurodegenerative factors may be important for cognitive function.
Authors: Bruce Fischl; David H Salat; Evelina Busa; Marilyn Albert; Megan Dieterich; Christian Haselgrove; Andre van der Kouwe; Ron Killiany; David Kennedy; Shuna Klaveness; Albert Montillo; Nikos Makris; Bruce Rosen; Anders M Dale Journal: Neuron Date: 2002-01-31 Impact factor: 17.173
Authors: Abraham Reichenberg; Philip D Harvey; Christopher R Bowie; Ramin Mojtabai; Jonathan Rabinowitz; Robert K Heaton; Evelyn Bromet Journal: Schizophr Bull Date: 2008-05-20 Impact factor: 9.306
Authors: Kathryn E Lewandowski; Julie M McCarthy; Dost Öngür; Lesley A Norris; Geoffrey Z Liu; Richard J Juelich; Justin T Baker Journal: Schizophr Res Date: 2018-08-17 Impact factor: 4.939
Authors: Shalaila S Haas; Ruiyang Ge; Nicole Sanford; Amirhossein Modabbernia; Abraham Reichenberg; Heather C Whalley; René S Kahn; Sophia Frangou Journal: Front Psychiatry Date: 2022-06-22 Impact factor: 5.435
Authors: Qiannan Zhao; Hengyi Cao; Wenjing Zhang; Siyi Li; Yuan Xiao; Carol A Tamminga; Matcheri S Keshavan; Godfrey D Pearlson; Brett A Clementz; Elliot S Gershon; Scot Kristian Hill; Sarah K Keedy; Elena I Ivleva; Rebekka Lencer; John A Sweeney; Qiyong Gong; Su Lui Journal: Neuropsychopharmacology Date: 2022-03-08 Impact factor: 8.294
Authors: Hayley F North; Jason Bruggemann; Vanessa Cropley; Vaidy Swaminathan; Suresh Sundram; Rhoshel Lenroot; Avril M Pereira; Andrew Zalesky; Chad Bousman; Christos Pantelis; Thomas W Weickert; Cynthia Shannon Weickert Journal: Eur Arch Psychiatry Clin Neurosci Date: 2021-03-24 Impact factor: 5.270
Authors: Nikolaos Koutsouleris; Lana Kambeitz-Ilankovic; Julian Wenzel; Shalaila S Haas; Dominic B Dwyer; Anne Ruef; Oemer Faruk Oeztuerk; Linda A Antonucci; Sebastian von Saldern; Carolina Bonivento; Marco Garzitto; Adele Ferro; Marco Paolini; Janusch Blautzik; Stefan Borgwardt; Paolo Brambilla; Eva Meisenzahl; Raimo K R Salokangas; Rachel Upthegrove; Stephen J Wood; Joseph Kambeitz Journal: Neuropsychopharmacology Date: 2021-03-15 Impact factor: 7.853
Authors: New Fei Ho; Benjamin J H Lee; Jordon X J Tng; Max Z Y Lam; Guoyang Chen; Mingyuan Wang; Juan Zhou; Richard S E Keefe; Kang Sim Journal: Eur Psychiatry Date: 2020-04-27 Impact factor: 5.361
Authors: Luis Alameda; Margot Fournier; Ines Khadimallah; Alessandra Griffa; Martine Cleusix; Raoul Jenni; Carina Ferrari; Paul Klauser; Philipp S Baumann; Michel Cuenod; Patric Hagmann; Philippe Conus; Kim Q Do Journal: Proc Natl Acad Sci U S A Date: 2018-11-19 Impact factor: 11.205